ABL Diagnostics SA ABLD

WOIPPY, France, September 30, 2026--Regulatory News: ABL Texcell Diagnostics (Euronext Paris: ABLD – ISIN: FR001400AHX6) (the "Company"), a company specializing in molecular diagnostic solutions, healthcare software and services supporting clinical research, announces that it has made its Half-Year Financial Report for the period ended 30 June 2026 available to the public and filed it with the French Financial Markets Authority (Autorité des Marchés Financiers – AMF).

WOIPPY, France, September 21, 2026--Regulatory News: ABL Diagnostics (Euronext Paris: ABLD – ISIN: FR001400AHX6) (the "Company"), a company specializing in molecular diagnostic solutions, healthcare software and clinical research services, announces that it has signed, alongside Advanced Biological Laboratories S.A. (ABL), its parent company, a non-binding letter of intent for a proposed acquisition of 100% of the share capital of Vela Operations Singapore Pte. Ltd. and Vela Diagnostics USA Inc.

WOIPPY, France, September 17, 2026--Regulatory News: ABL Diagnostics (Euronext Paris: ABLD – ISIN: FR001400AHX6) (the "Company"), a company specialized in molecular diagnostics solutions, healthcare software and services supporting clinical research, announces that its shareholders, meeting today in an Extraordinary General Meeting, approved the change of the Company's corporate name to ABL Texcell Diagnostics, reflecting the Company's evolution and the growing complementarity of its activities

WOIPPY, France, September 17, 2026--Regulatory News: ABL Diagnostics (Euronext Paris – Compartment B – ISIN: FR001400AHX6 – ABLD), an international company specializing in molecular diagnostic solutions, healthcare software and life sciences services, announces its participation in Investor Access @ Maison de la Chimie Paris 2026, with Paris events on October 6–7, 2026.

WOIPPY, France, September 15, 2026--Regulatory News: ABL Diagnostics (Euronext Paris – Compartment B – ISIN: FR001400AHX6 – ABLD), an international company specializing in molecular diagnostic solutions, healthcare software and life sciences services, announces its participation in the European Main MidCap Event Paris 2026, to be held on September 30 and October 1, 2026 at the Four Seasons Hotel George V in Paris.

WOIPPY, France, September 14, 2026--Regulatory News: ABL Diagnostics (Euronext Paris: ABLD – ISIN: FR001400AHX6) (the "Company"), a company specializing in molecular diagnostic solutions, healthcare software and clinical research services, informs its shareholders and the broader financial community that the latest equity research report on the Company, prepared by All Invest Securities, is now available.

WOIPPY, France, September 11, 2026--Regulatory News: ABL Diagnostics (Euronext Paris: ABLD – ISIN: FR001400AHX6) (the "Company"), a company specialized in molecular diagnostics solutions, healthcare software and services supporting clinical research, today announced that it has filed, on Friday, September 11, 2026, a bid to acquire the business operations and assets of IntegraGen, a company specializing in genomic analysis of nucleic acids, particularly in oncology and rare genetic diseases, cur

TOULOUSE, France & FULLERTON, Calif., September 10, 2026--Regulatory News: ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a next-generation biopharmaceutical company developing innovative therapies for sepsis and critical care based on a proprietary apoA-I-based technology platform, announces the establishment of a strategic partnership with TEXCELL, a division of ABL Diagnostics, for the viral safety and clearance testing of its biopharmaceutical development.

WOIPPY, France, September 10, 2026--Regulatory News: ABL Diagnostics (Euronext Paris: ABLD - ISIN: FR001400AHX6), a company specializing in molecular diagnostic solutions, healthcare software and clinical research services, today announced the conclusion of a strategic partnership with ABIONYX Pharma (FR0012616852 – ABNX – PEA PME eligible), a next-generation biopharmaceutical company developing innovative therapies in sepsis and intensive care, based on an exclusive apoA-I-based technology plat

WOIPPY, France, September 08, 2026--Regulatory News: ABL Diagnostics (Euronext Paris: ABLD – ISIN: FR001400AHX6) (the "Company"), a company specializing in molecular diagnostic solutions, healthcare software and clinical research services, today reported its results for the first half ended June 30, 2026.

WOIPPY, France, August 27, 2026--Regulatory News: ABL Diagnostics (Paris:ABLD) informs its shareholders that they are invited to attend an Ordinary and Extraordinary General Meeting to be held on Thursday, September 17, 2026, at 11:00 a.m., at the offices of the law firm De Gaulle Fleurance & Associés, located at 9 rue Boissy d'Anglas, 75008 Paris, France.

WOIPPY, France, August 27, 2026--Regulatory News: ABL Diagnostics: (Paris:ABLD)

WOIPPY, France, July 29, 2026--Regulatory News: ABL Diagnostics (Paris:ABLD) announces that its main shareholder, Advanced Biological Laboratories (ABL), a Luxembourg-based diagnostics company, has filed information with the French Financial Markets Authority (AMF) via ONDE, the centralized information filing system, regarding the sale of a new block of ABL Diagnostics shares as part of an over-the-counter transaction with a private third party.

WOIPPY, France, July 27, 2026--Regulatory News: ABL Diagnostics (Euronext Compartment B – ISIN: FR001400AHX6), a company specialized in vitro diagnostics, announces that on 23 July 2026 an Amended and Restated Equity Line and Share Loan Agreement was executed, amending the initial Equity Line and Share Loan Agreement dated 16 October 2025. The revised agreement has been entered into between the Company's controlling shareholder, Advanced Biological Laboratories (ABL) SA ("ABL Lux"), and Alumni C

WOIPPY, France, July 23, 2026--Regulatory News: ABL Diagnostics (Euronext Paris – Compartment B – ISIN: FR001400AHX6), a company specialized in molecular diagnostics, healthcare software, and clinical sample management, announces that it has been selected by the Évry Commercial Court to acquire the assets and business operations of TEXCELL.

WOIPPY, France, July 15, 2026--Regulatory News: ABL Diagnostics (Euronext Paris – ISIN: FR001400AHX6 – Ticker: ABLD) announces that it was notified on Friday, July 10, 2026, by its reference shareholder, Advanced Biological Laboratories (ABL) S.A., a Luxembourg-registered company, that it has crossed below the threshold of 95% of ABL Diagnostics’ capital.

WOIPPY, France, July 02, 2026--Regulatory News: At the Annual General Meeting of ABL Diagnostics (Paris:ABLD) held on Tuesday, June 30, 2026, at 11:00 a.m., shareholders approved all resolutions submitted for their vote, including the payment of a dividend of €0.11 per share for the 2025 fiscal year (compared with €0.05 per share for the 2024 fiscal year), reflecting the Company's improved results and strong financial position.